1-6 of 6
Sara Cresta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PD7-09: A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)

Komal Jhaveri, Dejan Juric, Sara Cresta, Yoon-Sim Yap, Francois P Duhoux, Catherine Terret, Rachel Layman, Nicole Kundamal, Serena Liao, Yan Ji, Adam Crystal, Giuseppe Curigliano
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD7-09.
https://doi.org/10.1158/1538-7445.SABCS19-PD7-09
Published: 15 February 2020
View article titled, Abstract PD7-09: A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)
Journal Articles

Abstract P4-10-07: Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC

Komal Jhaveri, Dejan Juric, Sara Cresta, Yoon-Sim Yap, Francois P. Duhoux, Catherine Terret, Rachel Layman, Alejandro Balbin, Qing Sheng, Serena Liao, Adam Crystal, Giuseppe Curigliano
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-10-07.
https://doi.org/10.1158/1538-7445.SABCS19-P4-10-07
Published: 15 February 2020
View article titled, Abstract P4-10-07: Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC
Journal Articles

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer

Elvira D'Ippolito, Ilaria Plantamura, Lucia Bongiovanni, Patrizia Casalini, Sara Baroni, Claudia Piovan, Rosaria Orlandi, Ambra V. Gualeni, Annunziata Gloghini, Anna Rossini, Sara Cresta, Anna Tessari, Filippo De Braud, Gianpiero Di Leva, Claudio Tripodo, Marilena V. Iorio
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (18): 5562–5572.
https://doi.org/10.1158/0008-5472.CAN-16-0140
Published: 15 September 2016
View article titled, miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
Open the PDF for miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies

Maria Silvia Cona, Valter Torri, Massimo Di Nicola, Marina Garassino, Michele Del Vecchio, Sara Cresta, Diego Signorelli, Silvia Damian, Matteo Duca, Alice Indini, Monica Niger, Filippo de Braud
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3943.
https://doi.org/10.1158/1538-7445.AM2016-3943
Published: 15 July 2016
View article titled, Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies
Journal Articles

Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer

Patrick Schöffski, Sara Cresta, Ingrid A Mayer, Hans Wildiers, Isabelle Rooney, Doris Apt, Steve Gendreau, Kari Morrissey, Mark Lackner, Jill Spoerke, Eric Winer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-19-10.
https://doi.org/10.1158/1538-7445.SABCS14-P5-19-10
Published: 01 May 2015
View article titled, Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer
Journal Articles

Abstract LB-320: Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer.

Anna Tessari, Lorenzo Pilla, Biagio Paolini, Maria Luisa Carcangiu, Luigi Mariani, Angela Moliterni, Filippo De Braud, Sara Cresta
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-320.
https://doi.org/10.1158/1538-7445.AM2013-LB-320
Published: 15 April 2013
View article titled, Abstract LB-320: Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer.